Chemical Compound Review:
Esonarimod 2-(ethanoylsulfanylmethyl)-4- (4...
Synonyms:
KE-298, CHEMBL2003782, KE 298, AC1L2T05, Tox21_113282, ...
- Effect of KE-298 on experimental arthritis in mice. Nagai, H., Takaoka, Y., Mori, H., Kawada, K. Pharmacology (1996)
- Suppression of pulmonary granulomatous inflammation by immunomodulating agents. Hashimoto, M., Kobayashi, K., Yamagata, N., Katsura, T., Sugihara, S., Iwabuchi, H., Kasama, T., Kasahara, K., Takahashi, T., Takeshita, K. Agents Actions (1992)
- Expression of membrane-type 1 matrix metalloproteinase in rheumatoid synovial cells. Honda, S., Migita, K., Hirai, Y., Origuchi, T., Yamasaki, S., Kamachi, M., Shibatomi, K., Fukuda, T., Kita, M., Hida, A., Ida, H., Aoyagi, T., Kawakami, A., Kawabe, Y., Oizumi, K., Eguchi, K. Clin. Exp. Immunol. (2001)
- KE-298 and its active metabolite KE-758 suppress nitric oxide production by murine macrophage cells and peritoneal cells from rats with adjuvant induced arthritis. Inoue, T., Hamada, Y., Takeshita, K., Fukushima, K., Higaki, M. J. Rheumatol. (2001)
- Identification of rat urinary and biliary metabolites of esonarimod, a novel antirheumatic drug, using liquid chromatography/electrospray ionization tandem mass spectrometry with postcolumn addition of 2-(2-methoxyethoxy)ethanol, a signal-enhancing modifier. Yamaguchi, J., Ohmichi, M., Hasegawa, M., Yoshida, H., Ogawa, N., Higuchi, S. Drug Metab. Dispos. (2001)
- S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. Ohmi, N., Yoshida, H., Endo, H., Hasegawa, M., Akimoto, M., Higuchi, S. Xenobiotica (2003)
- Stereoselective pharmacokinetics of [14C]-labeled KE-298, a new anti-rheumatic drug, in rats. Yoshida, H., Kohno, Y., Endo, H., Hasegawa, M., Suwa, T. Chirality. (1996)
- Stereoselective disposition and chiral inversion of KE-298, a new antirheumatic drug, in rats. Yoshida, H., Kohno, Y., Endo, H., Ohmi, N., Fukushima, K., Suwa, T., Hayashi, M. Chirality. (1997)
- New disease-modifying antirheumatic drug 2 acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298) selectively augments activation-induced T cell death. Urayama, S., Kawakami, A., Nakashima, T., Yamasaki, S., Hida, A., Ida, H., Kamachi, M., Nakamura, H., Origuchi, T., Migita, K., Kawabe, Y., Eguchi, K. J. Lab. Clin. Med. (2001)
- KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Sugimoto, M., Inoue, T., Yamashita, M., Takeshita, K., Nakaike, S. Drugs under experimental and clinical research. (2002)
- Suppressive effects of the new antirheumatic drug KE-298 on TNF alpha-induced production of matrix metalloproteinases but not of tissue inhibitor-1 of metalloproteinases in human rheumatoid synoviocytes. Takahashi, S., Inoue, T., Higaki, M., Mizushima, Y. Drugs under experimental and clinical research. (1998)
- Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thioredoxin and on the level of intracellular glutathione in human monocytes and T cells. Sugimoto, M., Inoue, T., Takeshita, K., Nakamura, H., Yodoi, J. Mol. Immunol. (2002)
- The new antirheumatic drug KE-298 suppresses monocyte chemoattractant protein (MCP)-1 and RANTES production in rats with adjuvant-induced arthritis and in IL-1beta-stimulated synoviocytes of patients with rheumatoid arthritis. Inoue, T., Yamashita, M., Higaki, M. Rheumatol. Int. (2001)